Why Summit Therapeutics Stock Slipped Today

Source The Motley Fool

Summit Therapeutics (NASDAQ: SMMT) stock did better than a lot of other equities during an otherwise forgettable trading session on Wednesday. In contrast to other titles that fell notably, Summit more or less kept pace with the S&P 500 (SNPINDEX: ^GSPC), managing to dip by a relatively modest 2.25% in price. Some investors, at least, were cheered by an analyst's recommendation upgrade on the stock.

The high potential of a licensed drug

Well before market open, Citigroup pundit Yigal Nochomovitz changed his recommendation on Summit's shares to buy from neutral. Accompanying this was a generous price target increase; the analyst's fair value assessment is now $35 per share, where formerly it stood at $23.

Where to invest $1,000 right now? Our analyst team just revealed what they believe are the 10 best stocks to buy right now. Learn More »

According to reports, Nochomovitz wrote that his move was based on a concentrated analysis of the prospects for ivonescimab. This is a rather promising cancer drug Summit has licensed from Chinese peer Akeso. The pundit feels that the coming readout of the medication's Harmoni-2 late-stage clinical trial has a 70% chance of indicating a favorable result with overall survival rates.

Ivonescimab has already attracted much notice after Akeso divulged the results of a clinical trial pitting it against 2024's top-selling drug, Merck's blockbuster Keytruda, for the treatment of non-small cell lung cancer (NSCLC).

Uncertainty reigns

The recommendation upgrade is certainly heartening, but there are two factors mitigating this just now. First, as ever in the biotech world, a company's success depends on it bringing medications to market; ivonescimab's promise is only that at the moment, and much work still needs to be done before it can win potentially win approval from top regulators (let alone succeed as a commercialized product).

Second, there is still much uncertainty swirling around the tariffs President Trump aims to impose on certain trade partners next week. He has specifically mentioned the pharmaceutical sector as a target for such levies; however, his administration hasn't yet proffered many details of the extra costs importers will have to pay.

Don’t miss this second chance at a potentially lucrative opportunity

Ever feel like you missed the boat in buying the most successful stocks? Then you’ll want to hear this.

On rare occasions, our expert team of analysts issues a “Double Down” stock recommendation for companies that they think are about to pop. If you’re worried you’ve already missed your chance to invest, now is the best time to buy before it’s too late. And the numbers speak for themselves:

  • Nvidia: if you invested $1,000 when we doubled down in 2009, you’d have $312,980!*
  • Apple: if you invested $1,000 when we doubled down in 2008, you’d have $42,421!*
  • Netflix: if you invested $1,000 when we doubled down in 2004, you’d have $537,825!*

Right now, we’re issuing “Double Down” alerts for three incredible companies, and there may not be another chance like this anytime soon.

Continue »

*Stock Advisor returns as of March 24, 2025

Citigroup is an advertising partner of Motley Fool Money. Eric Volkman has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Merck and Summit Therapeutics. The Motley Fool has a disclosure policy.

Disclaimer: For information purposes only. Past performance is not indicative of future results.
placeholder
EUR/USD ticks lower despite uncertainty over US-China tradeEUR/USD edges lower to near 1.1400 during European trading hours on Tuesday. The major currency pair ticks lower as the US Dollar (USD) steadies, but remains broadly on edge amid escalating uncertainty about the trade outlook between the United States (US) and China.
Author  FXStreet
12 hours ago
EUR/USD edges lower to near 1.1400 during European trading hours on Tuesday. The major currency pair ticks lower as the US Dollar (USD) steadies, but remains broadly on edge amid escalating uncertainty about the trade outlook between the United States (US) and China.
placeholder
XRP Whale Makes $68.7 Million Coinbase Deposit—Cashing In On Price Surge?On-chain data shows an XRP whale has made a large inflow into the Coinbase exchange, a sign that could be bearish for the asset’s price.
Author  Bitcoinist
12 hours ago
On-chain data shows an XRP whale has made a large inflow into the Coinbase exchange, a sign that could be bearish for the asset’s price.
placeholder
Europe reeling from Trump’s first 100 days, says “we’ve never seen anything like this”European leaders say they’ve never dealt with anything like the first 100 days of Trump’s second term.
Author  Cryptopolitan
12 hours ago
European leaders say they’ve never dealt with anything like the first 100 days of Trump’s second term.
placeholder
EUR/JPY holds gains near 162.50, downside seems possible due to ECB’s dovish signalsEUR/JPY gains ground after registering more than 0.50% losses in the previous session, trading around 162.40 during European hours on Tuesday.
Author  FXStreet
12 hours ago
EUR/JPY gains ground after registering more than 0.50% losses in the previous session, trading around 162.40 during European hours on Tuesday.
placeholder
AUD/JPY climbs to near 91.50 as decreasing safe-haven demand weighs on Japanese YenAUD/JPY gains ground after registering more than 0.50% losses in the previous session, trading around 91.50 during the European hours on Tuesday.
Author  FXStreet
13 hours ago
AUD/JPY gains ground after registering more than 0.50% losses in the previous session, trading around 91.50 during the European hours on Tuesday.
goTop
quote